Metformin Geriatric (65+) Caregiver Administration Guidance

What actually changes after 65

The label's dosing section gives the same starting doses and the same 2,550 mg daily maximum for adults, with no separate older-adult schedule [1]. Its geriatric section adds one instruction: assess renal function more frequently [1].

The boxed warning is where age shows up directly. It lists age 65 or older among the risk factors for metformin-associated lactic acidosis, alongside renal impairment, radiological studies with contrast, surgery and other procedures, hypoxic states such as acute congestive heart failure, excessive alcohol intake, hepatic impairment and mitochondrial disease [1]. The label attributes the age-related risk to a greater likelihood of hepatic, renal or cardiac impairment in older patients [1].

So the caregiver's job after 65 is not a different dose. It is knowing the kidney number, knowing what else is on the medication list, and recognizing the symptoms the label warns about [1][2].

Kidney function decides everything

The label's renal rules are specific [1]:

• The label says to check eGFR before starting metformin and at least yearly in everyone taking it, and to assess renal function more frequently in older patients [1].
• Metformin is contraindicated at an eGFR below 30 mL/min/1.73 m² [1].
• Starting is not recommended at an eGFR of 30 to 45 [1].
• If eGFR later falls below 45, the label says to assess the benefit and risk of continuing [1].
• If eGFR falls below 30, the label says metformin is to be discontinued [1].

Metformin is not metabolized and is cleared unchanged by the kidneys. The label says the risk of metformin accumulation and lactic acidosis increases with the severity of renal impairment because metformin is substantially excreted by the kidney, and that half-life lengthens and clearance falls as renal function declines [1].

For a caregiver, two pieces of information belong on every visit summary — the eGFR value and the date it was drawn. The label's instruction for older patients is more frequent assessment, without naming a specific interval [1].

Lactic acidosis: what a caregiver would notice first

The boxed warning describes an onset that is often subtle and easy to dismiss: malaise, muscle aches, respiratory distress, sleepiness and abdominal pain. Severe acidosis has produced low blood pressure and resistant bradyarrhythmias [2]. The laboratory picture is a blood lactate above 5 mmol/L, an anion gap acidosis, a raised lactate-to-pyruvate ratio, and metformin plasma levels generally above 5 mcg/mL [2].

If lactic acidosis is suspected, the label says metformin is to be discontinued and general supportive measures started in a hospital setting, where prompt hemodialysis is recommended and has often reversed symptoms [1][2].

In day-to-day caregiving, the symptoms to keep visible are new muscle aching, unusual drowsiness, trouble breathing, and stomach pain — especially when renal impairment, an acute hypoxic illness such as congestive heart failure, excessive alcohol intake, hepatic impairment, recent contrast exposure, or surgery is also present, since those are the risk factors the label lists [1][2].

Contrast dye, surgery and procedures

Intravascular iodinated contrast can acutely reduce renal function, and the label says to stop metformin at the time of, or before, the procedure in patients with an eGFR of 30 to 60, a history of hepatic impairment, alcoholism or heart failure, or when contrast is given intra-arterially. eGFR is re-evaluated 48 hours after the procedure, and metformin restarted only if renal function is stable [1].

The label also says to discontinue metformin temporarily while a patient's food and fluid intake is restricted during surgery or another procedure, and to discontinue it when an acute hypoxic event occurs — acute congestive heart failure, cardiovascular collapse, heart attack or sepsis [1].

Practical point for a caregiver: the imaging or surgical team needs to know the patient takes metformin, and the most recent eGFR result is the useful number to bring [1].

Giving the dose: meals, tablets and hypoglycemia

Immediate-release metformin is taken with meals. Doses above 2,000 mg a day may be better tolerated split three times a day with meals [1]. Taking an 850 mg tablet with food lowers the peak blood level by about 40% and the total exposure by about 25% compared with taking it without food [1].

Extended-release metformin is different: start at 500 mg once daily with the evening meal, increase by 500 mg weekly to a maximum of 2,000 mg once daily, and swallow the tablet whole — never crush, cut or chew it [2]. A patient already on immediate-release can switch to extended-release at the same total daily dose, up to 2,000 mg once daily [2].

On hypoglycemia, the label's warning says the risk rises when metformin is combined with insulin or an insulin secretagogue, where lower doses of those drugs may be required [1].

GI side effects: the label's own numbers

In a U.S. trial of immediate-release metformin up to 2,550 mg a day, diarrhea occurred in 53% of 141 patients on metformin versus 12% of 145 on placebo, nausea or vomiting in 26% versus 8%, flatulence in 12% versus 6%, and diarrhea led to discontinuation in 6% [1].

In placebo-controlled trials of extended-release metformin, 781 patients on the drug and 195 on placebo, diarrhea occurred in 10% versus 3% and nausea or vomiting in 7% versus 2%, with diarrhea leading to discontinuation in 0.6% [2]. The label cautions that adverse reaction rates from different trials cannot be directly compared [1].

Over the Diabetes Prevention Program and its long-term follow-up, gastrointestinal symptoms were more common with metformin than placebo and declined over time [3].

Interactions to flag when a new prescription arrives

The label's interaction table names specific groups [1]:

• Carbonic anhydrase inhibitors — topiramate, zonisamide, acetazolamide, dichlorphenamide. They lower serum bicarbonate and can cause a non-anion gap acidosis, raising lactic acidosis risk; the label advises more frequent monitoring [1].
• Drugs that reduce metformin clearance through the OCT2 and MATE transport systems — ranolazine, vandetanib, dolutegravir and cimetidine. These can increase metformin exposure, and the label advises weighing benefits and risks [1].
• Alcohol. It potentiates metformin's effect on lactate metabolism, and the label warns against excessive intake [1].
• Insulin and insulin secretagogues such as sulfonylureas. These raise hypoglycemia risk, and lower doses may be needed [1].
• Drugs that raise blood glucose — thiazides and other diuretics, corticosteroids, phenothiazines, thyroid products, estrogens, oral contraceptives, phenytoin, nicotinic acid, sympathomimetics, calcium channel blockers and isoniazid. The label advises watching for loss of glycemic control when one is started and for hypoglycemia when one is withdrawn [1].

Beyond the table, the label advises more frequent monitoring whenever a patient takes drugs that impair renal function, cause significant hemodynamic change, affect acid-base balance, or increase metformin accumulation [1].

Vitamin B12 with long-term use

The label's warning section reports that in 29-week trials, a drop to subnormal B12 levels occurred in about 7% of patients on metformin. The label says the drop may be associated with anemia but appears rapidly reversible with discontinuation of metformin or with B12 supplementation, and it directs measuring hematologic parameters yearly and vitamin B12 every 2 to 3 years [1].

Longer-term data come from the Diabetes Prevention Program, a prediabetes population. Low B12 (203 pg/mL or less) was found in 4.3% of metformin users versus 2.3% of placebo at 5 years (P=0.02) and 7.4% versus 5.4% at 13 years (P=0.12). Low or borderline-low B12 (298 pg/mL or less) occurred in 19.1% versus 9.5% at 5 years (P<0.01) and 20.3% versus 15.6% at 13 years (P=0.02) [4]. The odds of deficiency rose 13% for each year of metformin use (OR 1.13, 95% CI 1.06 to 1.20) [4]. Anemia was more common with metformin but did not track B12 status, and neuropathy was more common among metformin users with low B12 [4].

Sick days, hospital stays and the medication list

During surgery or another procedure that restricts food and fluids, the metformin label says treatment should be temporarily discontinued [1]. The label also gives metformin instructions for iodinated contrast and for acute hypoxic events, so hospital teams need to know about these if they occur during a stay [1]. After discharge, the discharge instructions should say plainly whether metformin is to continue and at what dose.

For appointments, bring:

• A current medication list including over-the-counter drugs, vitamins and supplements.
• The most recent eGFR result with its date.
• The home glucose log, if the patient monitors.
• Notes on any stomach symptoms, unusual weakness, breathing changes or falls since the last visit.